脂可清胶囊对高脂血症患者血液炎症因子的影响

目的:探讨脂可清胶囊对高脂血症患者血液炎症因子的影响。方法:95例高脂血症患者随机分为治疗组47例和对照组48例,治疗组口服脂可清胶囊,3粒/次,3次/d;对照组口服辛伐他汀,20 mg,1次/d。疗程均8周,另设健康15例作为正常对照组。观察血脂水平,采用酶联免疫吸附试验(ELISA)法测定高敏C-反应蛋白(hs-CRP),白细胞介素-6(IL-6),血管性血友病因子(vWF)及同型半胱氨酸(Hcy)。结果:两组治疗后总胆固醇(TC),甘油三酯(TG)及高密度脂蛋白胆固醇(HDL-C)与正常对照组无显著差异;治疗后两组低密度脂蛋白(LDL-C)均较正常对照组高(P<0.05,P<0.01),治疗组低于对照组(P<0.05);治疗后对照组hs-CRP,IL-6高于正常对照组(P<0.01);治疗后治疗组hs-CRP和IL-6水平低于对照组(P<0.05),与正常对照组差异不明显;治疗后两组vWF和Hcy水平与正常对照组比较,差异不明显。结论:脂可清胶囊能有效调节脂代谢,能调节炎性因子,从而降低动脉硬化指数。

Influence of Zhikeqing Capsule on Blood Inflammatory Factors in Treatment of Patients with Hyperlipidemia

Objective: To investigate influence of Zhikeqing capsule on blood inflammatory factors in patients with hyperlipidemia. Method: Ninty-five patients with hyperlipidemia were randomly divided into treatment group of 47 cases and control group of 48 cases.Another 15 healthy cases were established as the normal control.The treatment was given oral Zhikeqing capsule 3 capsules tid; control group was received simvastatin 20 mg daily (all for 8 weeks).Blood lipid levels were determined and the enzyme-linked immunosorbent assay (ELISA) method was used for the determination of high sensitive C-reactive protein (hs-CRP), interleukin-6 (IL-6), von Willebrand factor (vWF) and homocysteine (Hcy). Result: After treatment, the differences in TC, TG and HDL-C between the two groups with the normal controls were not significant; however LDL-C in the two groups was higher than that in the normal control group (P<0.05, P<0.01), and the treatment group was better than the control group (P<0.05).After treatment hs-CRP and IL-6 in control group were higher than those of the normal control group (P<0.01); in the treatment group, hs-CRP and IL-6 were lower than those of the control group (P<0.05) and without significant difference to the normal controls.After treatment, vWF and Hcy in treatment group and the control group showed no significant difference with the normal controls. Conclusion: Zhikeqing capsule can regulate lipid metabolism, adjust inflammatory factor, so as to reduce arterial stiffness index.